damian garde

some stories

  • In the race to develop a coronavirus treatment, Regeneron thinks it has the inside track

  • A new treatment promises to make little people taller. Is it an insult to ‘dwarf pride’?

  • Is sexual desire a medical issue? An experimental drug for women revives an intense debate

  • At MIT, a bitter dispute over research puts a scientist’s prestige on the line

  • ‘What’s my real identity?’: As DNA ancestry sites gather more data, the answer for consumers often changes

  • Their tissue turns to bone. Their joints freeze in place. And, finally, their hopes for treatment may be realized

  • So good it hurts: Why drug makers looking to replace opioids want to keep some pain in the picture

  • The reinvention of Bob Hugin: Amid anger over drug prices, a former pharma CEO makes a run for the Senate

  • Three years after steep price hike, Martin Shkreli’s drug company is losing money, documents show

  • Investigators say his fingerprints are all over financial crimes at Theranos. Why is he a virtual ghost?

  • Biotech tries to break bread with Silicon Valley’s disruptors. It’s awkward

  • How will biotech’s latest bubble go pop? We asked some experts

  • Biotech hedge fund titan Sam Isaly harassed, demeaned women for years, former employees say

  • How did biotech become a Hollywood supervillain?

  • How a drug ad made its way into ‘General Hospital’

  • Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

  • That’s ‘what I call’ innovation: The bons mots of Patrick Soon-Shiong